Cargando…

First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study

Breast cancer is the most common malignant disease and among the most frequent causes of cancer mortality in females worldwide. Metastatic breast cancer (MBC) is conventionally considered to be incurable. In first-line treatment of HER-2 positive MBC, randomized trials have demonstrated that trastuz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aitelhaj, Meryem, Lkhoyaali, Siham, Rais, Ghizlane, Boutayeb, Saber, Errihani, Hassan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The African Field Epidemiology Network 2016
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5267845/ https://www.ncbi.nlm.nih.gov/pubmed/28154679 http://dx.doi.org/10.11604/pamj.2016.24.324.4058

Ejemplares similares

Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients
por: Aitelhaj, Meryem, et al.
Publicado: (2013)

Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study
por: Boulaamane, Lamiaa, et al.
Publicado: (2012)

Neoadjuvant chemotherapy in well-differentiated fetal adenocarcinoma: a case report
por: Lkhoyaali, Sihame, et al.
Publicado: (2014)

Les effets bénéfiques de l'accompagnement du patient cancéreux: particularités du Maroc
por: Lkhoyaali, Sihame, et al.
Publicado: (2014)

Radiation induced esophageal adenocarcinoma in a woman previously treated for breast cancer and renal cell carcinoma
por: Raissouni, Soundouss, et al.
Publicado: (2012)

Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology
por: Rais, Ghizlane, et al.
Publicado: (2012)

Primary pleural leiomyosarcoma with rapid progression and fatal outcome: a case report
por: Rais, Ghizlane, et al.
Publicado: (2012)

Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab
por: Nevala-Plagemann, Christopher, et al.
Publicado: (2019)

Metastatic ameloblastoma responding to combination chemotherapy: case report and review of the literature
por: Amzerin, Mounia, et al.
Publicado: (2011)

Estimation of the cost of treatment by chemotherapy for early breast cancer in Morocco
por: Boutayeb, Saber, et al.
Publicado: (2010)

Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer
por: Dai, Wei Fang, et al.
Publicado: (2022)

Classic Kaposi's sarcoma in morocco: clinico -epidemiological study at the national institute of oncology
por: Errihani, Hassan, et al.
Publicado: (2011)

Maladie de hodgkin et cancer colique secondaire: à propos d'un cas
por: Boulaâmane, Lamia, et al.
Publicado: (2011)

Spermatocytic seminoma at the National Institute of Oncology in Morocco
por: Raiss, Ghizlane G, et al.
Publicado: (2011)

La langue noire villeuse: après chimiothérapie
por: Lkhoyaali, Sihame, et al.
Publicado: (2014)

Breast and splenic metastases of squamous cell carcinoma from the uterine cervix: a case report
por: Aitelhaj, Meryem, et al.
Publicado: (2014)

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
por: Chung, Hyun Cheol, et al.
Publicado: (2020)

Sarcomatoid Carcinoma of the Lung: A Model of Resistance of Chemotherapy
por: Ouziane, Imane, et al.
Publicado: (2014)

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
por: Hua, Xin, et al.
Publicado: (2022)

Knowledge of risk factors, beliefs and practices of female healthcare professionals towards breast cancer, Morocco
por: Ghanem, Samia, et al.
Publicado: (2011)

Use of Medicinal Plants by Cancer Patients Under Chemotherapy in the Northwest of Morocco (Rabat Area) : Cross-Sectional Study
por: El Orfi, Nadia, et al.
Publicado: (2022)

The evolution of the socio-cultural and religious characteristics of cancer patients in Morocco: case of the National Institute of Oncology Rabat
por: Elkhalloufi, Fahd, et al.
Publicado: (2021)

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
por: Yu, Y. F., et al.
Publicado: (2017)

A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer
por: Macpherson, Iain R., et al.
Publicado: (2019)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
por: Saavedra Santa Gadea, Omar, et al.
Publicado: (2017)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

Triple malignancy in a single patient including a cervical carcinoma, a basal cell carcinoma of the skin and a neuroendocrine carcinoma from an unknown primary site: A case report and review of the literature
por: Mesmoudi, Mohamed, et al.
Publicado: (2011)

Trastuzumab plus pertuzumab in combination with chemotherapy in metastatic HER2-positive breast cancer: a retrospective single-armed cohort study in China
por: Qian, Yu, et al.
Publicado: (2022)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?
por: Sbitti, Yassir, et al.
Publicado: (2011)

Reduction in HER-2 protein expression in a breast tumor HER-2 positive after only one injection of Trastuzumab: a case report
por: Elghissassi, Ibrahim, et al.
Publicado: (2009)

Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial
por: Chan, A, et al.
Publicado: (2006)

Physical activity in cancer care: barriers and interventions
por: Azemmour, Youness, et al.
Publicado: (2022)

Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial
por: Shitara, Kohei, et al.
Publicado: (2019)

Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study
por: Xu, Binghe, et al.
Publicado: (2016)

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
por: Miller, Kathy, et al.
Publicado: (2016)

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study
por: Pegram, Mark D., et al.
Publicado: (2018)

Primary osteosarcoma of the breast: case report
por: Saber, Boutayeb, et al.
Publicado: (2008)

A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients
por: Zhu, Bo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0d0aq234jpc4ifm8f3he9ev7ca